Abstract 6380: Targeted delivery of RNA using synthetic bacterial spores.

Abstract Background: RNA therapy holds increasing promise for the treatment of various diseases. Delivering RNA, however, typically requires encapsulation in lipid nanoparticles, and a limitation of this technology is achieving tissue specificity beyond the liver and kidneys. We previously reported synthetic bacterial spore-like particles, termed “SSHELs,” for targeted cargo delivery [1]. SSHELs, composed of defined, biocompatible materials, were shown to specifically bind to HER2-positive cancer cells and accumulate in tumors [2]. This study explores whether SSHELs can deliver RNA to tissue-specific locations, focusing on HER2-positive cells. Methods: The experimental approach involved protein purification, SSHEL assembly, mRNA and siRNA loading, and assessing RNA delivery specificity via confocal microscopy and flow cytometry. In vitro and in vivo assays were conducted to assess the production of EGFP and luciferase in target cells. Experimental models included cell cultures and mice. Results: By decorating SSHELs with anti-HER2 affibodies and modulating lipid composition, we achieved specific mRNA and siRNA delivery to HER2-positive cells, resulting in selective protein induction or silencing. Loading SSHELs with RNA was highly efficient (∼95%), yielding thousands of transcripts per particle. In further investigations, we observed a distinctive feature of SSHELs made with DOTAP: they did not elicit or suppress inflammatory cytokine production (e.g., TNF-α, IL-6). This characteristic is noteworthy, as it suggests the biocompatibility and immunologically inert nature of SSHELs formulated with DOTAP. Ongoing in vivo experiments are assessing the efficacy of mRNA-loaded SSHELs in delivering cargo to HER2-positive tumors. Conclusions: SSHELs represent a novel approach in RNA therapeutics due to their unique characteristics. These particles, which mimic the structure of bacterial spores, provide a biocompatible and versatile platform for the targeted delivery of myriad therapeutics, such as small molecules, peptides, and RNAs. References: 1. Wu, I.-L., et al. (2015). A versatile nano display platform from bacterial spore coat proteins. Nature Communications, 6, 6777. 2. Kong, M., D’Atri, D., et al. (2023). Cell-specific cargo delivery using synthetic bacterial spores. Cell Reports, 42(1), 111955. Citation Format: Federico Machinandiarena, Domenico D'Atri, David J. Fitzgerald, Kumaran S. Ramamurthi, . Targeted delivery of RNA using synthetic bacterial spores [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 6380.

Authors

Institutions

Publication Details

Journal
Cancer Research
Published
2026-04-03
DOI
https://doi.org/10.1158/1538-7445.am2026-6380
Primary Topic
Cancer Research and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Abstract 6380: Targeted delivery of RNA using synthetic bacterial spores.

Federico Machinandiarena, Kumaran S. Ramamurthi, David J. FitzGerald, Domenico D'Atri
Cancer Research
Cancer Research and Treatments
article

Abstract 6380: Targeted delivery of RNA using synthetic bacterial spores.

Federico Machinandiarena, Kumaran S. Ramamurthi, David J. FitzGerald, Domenico D'Atri
article en

Abstract

Abstract Background: RNA therapy holds increasing promise for the treatment of various diseases. Delivering RNA, however, typically requires encapsulation in lipid nanoparticles, and a limitation of this technology is achieving tissue specificity beyond the liver and kidneys. We previously reported synthetic bacterial spore-like particles, termed “SSHELs,” for targeted cargo delivery [1]. SSHELs, composed of defined, biocompatible materials, were shown to specifically bind to HER2-positive cancer cells and accumulate in tumors [2]. This study explores whether SSHELs can deliver RNA to tissue-specific locations, focusing on HER2-positive cells. Methods: The experimental approach involved protein purification, SSHEL assembly, mRNA and siRNA loading, and assessing RNA delivery specificity via confocal microscopy and flow cytometry. In vitro and in vivo assays were conducted to assess the production of EGFP and luciferase in target cells. Experimental models included cell cultures and mice. Results: By decorating SSHELs with anti-HER2 affibodies and modulating lipid composition, we achieved specific mRNA and siRNA delivery to HER2-positive cells, resulting in selective protein induction or silencing. Loading SSHELs with RNA was highly efficient (∼95%), yielding thousands of transcripts per particle. In further investigations, we observed a distinctive feature of SSHELs made with DOTAP: they did not elicit or suppress inflammatory cytokine production (e.g., TNF-α, IL-6). This characteristic is noteworthy, as it suggests the biocompatibility and immunologically inert nature of SSHELs formulated with DOTAP. Ongoing in vivo experiments are assessing the efficacy of mRNA-loaded SSHELs in delivering cargo to HER2-positive tumors. Conclusions: SSHELs represent a novel approach in RNA therapeutics due to their unique characteristics. These particles, which mimic the structure of bacterial spores, provide a biocompatible and versatile platform for the targeted delivery of myriad therapeutics, such as small molecules, peptides, and RNAs. References: 1. Wu, I.-L., et al. (2015). A versatile nano display platform from bacterial spore coat proteins. Nature Communications, 6, 6777. 2. Kong, M., D’Atri, D., et al. (2023). Cell-specific cargo delivery using synthetic bacterial spores. Cell Reports, 42(1), 111955. Citation Format: Federico Machinandiarena, Domenico D'Atri, David J. Fitzgerald, Kumaran S. Ramamurthi, . Targeted delivery of RNA using synthetic bacterial spores [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 6380.

Cancer ResearchVol. 86(7_Supplement)
National Institutes of Health (US)
Openalex Percentile: Top 30%
Cancer Research and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.